VIS832

VIS832 is a humanized IgG1κ monoclonal antibody that targets human CD138 (syndecan-1), a surface antigen highly expressed on multiple myeloma (MM) cells. It is engineered for high binding avidity and mediates potent anti-tumor effects through enhanced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) via natural killer (NK) cells and macrophages, respectively. Unlike CD38-targeting agents such as daratumumab, VIS832 spares NK cells, allowing for robust immune-mediated MM cell killing even in resistant populations. In preclinical models, VIS832 demonstrated efficacy as monotherapy and showed synergistic activity when combined with standard-of-care agents such as lenalidomide or bortezomib, with evidence for superior tumor eradication and extended survival in animal models. Its differentiated targeting and mechanism suggest clinical potential for relapsed/refractory and newly diagnosed multiple myeloma[1][5][6][3][7].